Sanofi-Aventis Zimulti (correction)
Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...
You may also be interested in...
A substantial portion of European patients purchasing Sanofi-Aventis' Acomplia pay entirely out-of-pocket for the obesity drug
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.
Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.